These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 9280665)

  • 1. [Drug-related motor disorders in aged people].
    Martí-Massó JF
    Rev Neurol; 1997 Jul; 25 Suppl 1():S37-43. PubMed ID: 9280665
    [No Abstract]   [Full Text] [Related]  

  • 2. [Various encephalopathies caused by drugs].
    Uldry PA; Regli F; Naegeli C
    Schweiz Rundsch Med Prax; 1989 Jun; 78(23):658-62. PubMed ID: 2568672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    Mov Disord; 1998 Sep; 13(5):798-802. PubMed ID: 9756148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
    Smith LA; Tel BC; Jackson MJ; Hansard MJ; Braceras R; Bonhomme C; Chezaubernard C; Del Signore S; Rose S; Jenner P
    Mov Disord; 2002 Sep; 17(5):887-901. PubMed ID: 12360537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset.
    Hill MP; Bezard E; McGuire SG; Crossman AR; Brotchie JM; Michel A; Grimée R; Klitgaard H
    Mov Disord; 2003 Nov; 18(11):1301-5. PubMed ID: 14639671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The hyperkinetic abnormal movements scale: a tool for measuring levodopa-induced abnormal movements in squirrel monkeys.
    Tan LC; Protell PH; Langston JW; Togasaki DM
    Mov Disord; 2002 Sep; 17(5):902-9. PubMed ID: 12360538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel pattern of levodopa-related motor fluctuations: 'paradoxical'on.
    Kim HJ; Kim JY; Ha Paek S; Jeon BS
    Parkinsonism Relat Disord; 2008; 14(4):281-5. PubMed ID: 17980642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug-induced parkinsonism].
    Shiio Y
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():377-81. PubMed ID: 18072346
    [No Abstract]   [Full Text] [Related]  

  • 9. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa-related motor complications--phenomenology.
    Fox SH; Lang AE
    Mov Disord; 2008; 23 Suppl 3():S509-14. PubMed ID: 18781677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug induced dyskinesia].
    Kondo T; Ishiguchi H
    Nihon Naika Gakkai Zasshi; 2007 Aug; 96(8):1621-6. PubMed ID: 17802711
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa].
    Svetel MV; Sternić NM; Filipović SR; Vojvodić NM; Kostić VS
    Srp Arh Celok Lek; 1997; 125(7-8):203-6. PubMed ID: 9304232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Samadi P; Grégoire L; Rouillard C; Bédard PJ; Di Paolo T; Lévesque D
    Ann Neurol; 2006 Feb; 59(2):282-8. PubMed ID: 16437566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa, motor complications and disease progression.
    Deleu D
    J Neurol Sci; 2008 Oct; 273(1-2):155-6; author reply 156-7. PubMed ID: 18620710
    [No Abstract]   [Full Text] [Related]  

  • 15. Levodopa can worsen tremor associated with dystonia.
    Hensman DJ; Bain PG
    Mov Disord; 2006 Oct; 21(10):1778-80. PubMed ID: 16856131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical pharmacology of dyskinesias induced by L-dopa in Parkinsonian patients].
    Rascol O; Brefel-Courbon C; Blin O
    Therapie; 1998; 53(1):43-8. PubMed ID: 9773099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia.
    Reddy S; Factor SA; Molho ES; Feustel PJ
    Mov Disord; 2002 Jul; 17(4):676-81. PubMed ID: 12210856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
    Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
    Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Psychiatric complications of L-dopa: physiopathology and treatment].
    Castro-García A
    Rev Neurol; 1997 Aug; 25 Suppl 2():S157-62. PubMed ID: 9280683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
    Visanji NP; Gomez-Ramirez J; Johnston TH; Pires D; Voon V; Brotchie JM; Fox SH
    Mov Disord; 2006 Nov; 21(11):1879-91. PubMed ID: 16960862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.